论文部分内容阅读
目的探讨心脑宁胶囊在脑梗死偏瘫患者治疗和康复中的临床疗效。方法选取2012年1月至2014年1月我院神经内科收治的60例脑梗死偏瘫患者,采用随机对照方法将其分为观察组和对照组。对照组(B组)给予常规治疗、康复训练和二级预防;观察组(A组)在此基础上口服心脑宁胶囊(贵州安泰药业有限公司,国药准字H20025697,规格:0.45 g/粒),每次1.35 g,每日3次口服,连续用药6个月。于患者入院时及系统康复训练6个月后进行神经功能残缺(NIHSS)评分,并采用Brunnstrom分级法评定肢体运动功能、Barthel氏指数(BI)评定日常生活能力(ADL)。结果经过6个月的康复治疗,60例患者NIHSS评分和BI均有不同程度改善。A组康复前后NIHSS评分差值为5.2±1.8,B组为3.5±1.3;A组康复前后BI差值为40.0±11.0,B组为21.2±7.3;A组改善程度均显著高于B组(P<0.05)。结论对于脑梗死偏瘫患者,心脑宁胶囊可有效辅助改善患者临床症状,促进神经功能恢复。
Objective To investigate the clinical effect of Xinnaoning Capsule in the treatment and rehabilitation of hemiplegia patients with cerebral infarction. Methods From January 2012 to January 2014, 60 patients with hemiplegia of cerebral infarction admitted to Department of Neurology of our hospital were randomly divided into observation group and control group. The control group (group B) was given routine treatment, rehabilitation training and secondary prevention. On the basis of this observation group (group A), oral administration of Xinnaoning Capsule (Guizhou Antai Pharmaceutical Co., Ltd., Zhunzi H20025697, specification: 0.45 g / Tablets), 1.35 g each time, 3 times daily oral administration, continuous medication for 6 months. Neurological impairment (NIHSS) was assessed at 6 months after admission and after systematic rehabilitation training. Physical motor function was assessed by Brunnstrom grading and Bartlett’s (BI) was used to assess daily living ability (ADL). Results After six months of rehabilitation, NIHSS scores and BI in 60 patients improved to some extent. The difference of NIHSS score before and after rehabilitation in group A was 5.2 ± 1.8 and in group B was 3.5 ± 1.3; the BI difference before and after rehabilitation in group A was 40.0 ± 11.0 and in group B was 21.2 ± 7.3; the improvement in group A was significantly higher than that in group B P <0.05). Conclusion For hemiplegia patients with cerebral infarction, Xinnaoning Capsule can effectively improve the clinical symptoms of patients and promote neurological recovery.